研究と業績　2023年

研究と業績　2023年

英文

  1. Nakahama K, Izumi M, Yoshimoto N, Fukui M, Sugimoto A, Nagamine H, Ogawa K, Sawa K, Tani Y, Kaneda H, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T. Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer. Cancer Chemother Pharmacol. 2023;92(5):381-390.
  2. Nakahama K, Izumi M, Yoshimoto N, Fukui M, Sugimoto A, Nagamine H, Ogawa K, Sawa K, Tani Y, Kaneda H, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T. Vimentin expression correlates with immune checkpoint inhibitor efficacy in non-small cell lung cancer. Cancer. 2023;129(15):2297-2307.
  3. Tani Y, Kaneda H, Koh Y, Tamiya A, Isa S, Kubo A, Ogawa K, Matsumoto Y, Sawa K, Yoshimoto N, Mitsuoka S, Kawaguchi T. The Impact of Estrogen Receptor Expression on Mutational Status in the Evolution of Non-Small Cell Lung Cancer. Clin Lung Cancer. 2023;24(2):165-174.
  4. Nagamine H, Yashiro M, Yoshimoto N, Izumi M, Sugimoto A, Nakahama K, Ogawa K, Matsumoto Y, Sawa K, Tani Y, Kaneda H, Mitsuoka S, Yamada K, Watanabe T, Aasai K, Fukumura K, Mayeda A, Kawaguchi T. RBM17 Expression Is Associated With the Efficacy of ICI Monotherapy in NSCLC With Low PD-L1 Expression. Anticancer Res. 2023;43(10):4663-4672.
  5. Nakahama K, Izumi M, Yoshimoto N, Fukui M, Sugimoto A, Nagamine H, Ogawa K, Sawa K, Tani Y, Kaneda H, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T. Influence of Smoking History on the Effectiveness of Immune-checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer: Analysis of Real-world Data. Anticancer Res. 2023;43(5):2185-2197.
  6. Takahashi M, Takahashi K, Kaneda H, Kawaguchi T, Otori T, Nakamura Y. Analysis of Risk Factors for Febrile Neutropenia in Patients with Small-Cell Lung Cancer Receiving Carboplatin Plus Etoposide Therapy. Oncology. 2024;102(7):565-573.
  7. Sawa K, Ihara Y, Imai T, Sugimoto A, Nagamine H, Ogawa K, Nakahama K, Matsumoto Y, Tani Y, Kaneda H, Mitsuoka S, Kawaguchi T, Shintani A. Lack of Association Between Immunotherapy and Improvement of Survival for Non-small Cell Lung Cancer Patients With Hemodialysis: A Nationwide Retrospective Cohort Study. Clin Lung Cancer. 2024;25(2):144-150.e3.
  8. Nakai T, Watanabe T, Kaimi Y, Shiomi K, Ando K, Miyamoto A, Ogawa K, Matsumoto Y, Sawa K, Sato K, Asai K, Matsumoto Y, Mikami Y, Ohsawa M, Kawaguchi T. Diagnostic Utility and Safety of Non-Intubated Cryobiopsy Technique Using a Novel Ultrathin Cryoprobe in Addition to Conventional Biopsy Techniques for Peripheral Pulmonary Lesions. Respiration. 2023;102(7):503-514.
  9. Ikeda S, Tsuboi M, Sakai K, Misumi T, Akamatsu H, Shoda H, Sakakura N, Nakamura A, Ohde Y, Hayashi H, Okishio K, Okada M, Yoshino I, Okami J, Takahashi K, Ikeda N, Tanahashi M, Tambo Y, Saito H, Toyooka S, Inokawa H, Chen-Yoshikawa T, Yokoyama T, Okamoto T, Yanagitani N, Oki M, Takahama M, Sawa K, Tada H, Nakagawa K, Mitsudomi T, Nishio K. NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC: translational research of phase III IMPACT study. Mol Oncol. 2024;18(2):305-316.
  10. Tanizaki, Kuroda H, Yokoyama T, Takahama M, Shoda H, Nakamura A, Kitamura Y, Mamesaya N, Kadota Y, Sawa K, Okishio K, Okada M, Suminaka C, Noda K, Sakai K, Chiba Y, Nishio K, Chamoto K, Honjo T, Yamamoto N, Nakagawa K, Hayashi H. Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy. JTO Clin Res Rep. 2023;13;4(12):100590.
  11. Shimomura Y, Sawa K, Imai T, Ihara Y, Yoshida H, Shintani A. Treatment sequencing after failure to alectinib in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. Cancer Sci. 2024;115(3):926-936.
  12. Sawa K, Sato I, Takeuchi M, Kawakami K. Risk of pneumonitis in non-small cell lung cancer patients with preexisting interstitial lung diseases treated with immune checkpoint inhibitors: a nationwide retrospective cohort study. Cancer Immunol Immunother. 2023;72(3):591-598.
  13. Nagamine H, Nakai T, Ueda T, Nakahama K, Sawa K, Yamada K, Watanabe T, Aasai K, Kawaguchi T. Tract creation with a 25-gauge needle for convex endobronchial ultrasound-guided core biopsy in intrapulmonary lesions adjacent to bronchi: three case reports. Transl Lung Cancer Res. 2023; 26;12(12):2550-2557.
  14. Ihara Y, Sawa K, Imai T, Kimura T, Otani M, Kawai R, Takatori S, Shintani A. Renin-angiotensin-aldosterone system inhibitors are associated with improved paclitaxel-induced peripheral neuropathy in lung cancer: a study using administrative claims data. Support Care Cancer. 2023;29;31(12):730.
  15. Kobayashi M, Miyamoto A, Watanabe T, Sawa K, Sato K, Yamada K, Yoshii N, Yamada K, Kawamoto K, Uji M, Shiraishi S, Asai K, Kakeya H, Kawaguchi T. COVID-19 vaccination benefits in preventing severe disease in mild-to-moderate cases: An analysis in the first specialized hospital for COVID-19 in Japan. Respir Investig. 2023;61(2):230-239.
  16. Nakai T, Matsumoto Y, Ueda T, Kuwae Y, Tanaka S, Miyamoto A, Matsumoto Y, Sawa K, Sato K, Yamada K, Watanabe T, Asai K, Furuse H, Uchimura K, Imabayashi T, Uenishi R, Fukui M, Tanaka H, Ohsawa M, Kawaguchi T, Tsuchida T. Comparison of the specimen quality of endobronchial ultrasound-guided intranodal forceps biopsy using standard-sized forceps versus mini forceps for lung cancer: A prospective study. Respirology. 2024 May;29(5):396-404. doi: 10.1111/resp.14659. Epub 2024 Jan 21.
  17. Kawaguchi T. Ethnic differences in lung cancer: "we can differ and still unite around common goals.". Respir Investig. 2023 May;61(3):355-356. doi: 10.1016/j.resinv.2023.02.002. Epub 2023 Mar 22.

和文

  1. 西村 美沙子, 澤 兼士, 浅井 一久. 【オーバーラップする呼吸器疾患の臨床像】COPDと肺癌. 呼吸器内科 2023;43:39-44.